At a glance
ClinicalIndex Comparison RecordN/ACompleted· 192 enrolled
Drug / intervention
Lacosamidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multi-center, Observational, Drug-utilization Study in Belgium to Evaluate the Use of VIMPAT® in Clinical Practice as Adjunctive Treatment of Partial Onset Epilepsy in Subjects Aged 16 and Older.
In Brief
An observational study evaluating Lacosamide for Seizures. Completed, enrolled 192 participants across 17 sites.
Detailed Summary
Observational study at the request of the Belgian Institut National d'Assurance Maladie-Invalidité / Rijksinstituut voor Ziekte-en Invaliditeits Verzekering INAMI/RIZIV: * type of patient treated with VIMPAT® * VIMPAT® dose * Effect of VIMPAT® on evolution of seizure control * Persistence rate at 6 months in terms of treatment duration * Discontinuation rate * Description of any changes in other epilepsy therapies * Safety and tolerability
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSeizures
CountriesBelgium
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedNov 2010
Primary CompletionMar 2012
TodayJul 2026
First PostedNov 8, 2010
Enrollment StartSep 1, 2010
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 15.7 years ago
Interventions
Lacosamidedrug